Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of breast cancer associated with a poor prognosis when sub-optimally treated. Recent advances include new and effective targeted therapies that have significantly improved outcomes for patients. Despite these advances, there are significant gaps across Canada, underscoring the need for evidence-based consensus guidance to inform treatment decisions. Addressing these gaps is crucial to ensuring that effective therapies are integrated into clinical practice, so as to improve the lives of patients affected by this aggressive form of breast cancer. The Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance is a standing nucleus committee of clinical-academic oncologists across Canada and Breast Cancer Canada, a patient organization. The mandate of this group is to provide evidence-based guidance on best practices in the management of patients with breast cancer. These consensus recommendations were developed using a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% of voters agreeing with the recommendation as written. There are 9 recommendations in the early setting; 7 recommendations in the metastatic setting; and 10 recommendations for patients with brain metastases.
Authors
- Kara Laing
- Christine Brezden‐Masley (ORCID: https://orcid.org/0000-0002-4818-318X)
- Nathaniel Bouganim (ORCID: https://orcid.org/0000-0003-0811-876X)
- Jan‐Willem Henning (ORCID: https://orcid.org/0009-0001-5768-6379)
- Marc Webster
- Anil A. Joy (ORCID: https://orcid.org/0000-0003-4201-8930)
- Mita Manna (ORCID: https://orcid.org/0000-0003-4344-7913)
- Ipshita Prakash (ORCID: https://orcid.org/0000-0002-0730-5363)
- Christine Simmons
- Muriel Brackstone (ORCID: https://orcid.org/0000-0002-7741-2199)
- David W. Cescon (ORCID: https://orcid.org/0000-0002-1080-0998)
- Karen A. Gelmon (ORCID: https://orcid.org/0000-0003-4111-2757)
- Sandeep R. Sehdev (ORCID: https://orcid.org/0000-0001-7434-2263)
- Stephen Chia (ORCID: https://orcid.org/0000-0001-7070-4386)
- Ian S. Dayes (ORCID: https://orcid.org/0000-0001-8550-1485)
- Jean-François Boileau (ORCID: https://orcid.org/0000-0002-9406-0375)
- John Hilton (ORCID: https://orcid.org/0000-0002-6280-8633)
- Jeffrey Cao (ORCID: https://orcid.org/0009-0006-6747-7083)
- Katarzyna J. Jerzak
- Scott Edwards
Institutions
- Mount Sinai Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- Juravinski Cancer Centre (CA)
- Ottawa Hospital (CA)
- McGill University Health Centre (CA)
- Jewish General Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Saskatchewan Cancer Agency (CA)
- Dr. H. Bliss Murphy Cancer Centre (CA)
- St Joseph's Health Care (CA)
Publication Details
- Journal
- Current Oncology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.3390/curroncol31110484
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Purdue University
- Celgene
- Genomic Health
- Helsinn
- McGill University
- Myriad Genetics
- BeiGene
- Seagen
- University of Toronto
- Eisai
- Astellas Pharma
- Ipsen
- Genentech
- Canadian Institutes of Health Research
- Daiichi Sankyo Europe